BioCardia, Inc. (BCDA): Nasdaq/NYSE listing notice — BioCardia receives Nasdaq delisting notice for equity shortfall; has until May 25 to submit compliance plan

BioCardia, Inc.

Stockholders' equity was $895,000 as of Dec. 31, 2025, well below the $2.5M minimum required by Nasdaq Listing Rule 5550(b)(1).
Notice received April 10, 2026; company must submit a plan to regain compliance by May 25, 2026.
If Nasdaq accepts the plan, it may grant up to 180 days from April 10 to evidence compliance.
Common stock continues trading on Nasdaq Capital Market under symbol BCDA; no immediate effect on listing.
Failure to regain compliance could lead to delisting; company intends to submit a plan and may request a hearing if plan is rejected.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BioCardia, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 10, 2026, BioCardia, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s stockholders’ equity of $895,000 as of December 31, 2025, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until May 25, 2026 to provide Nasdaq with a plan to regain compliance with the foregoing listing requirement. If the Company’s plan to regain compliance is acc

View on SEC.gov

Browse all listing & compliance notices →

BioCardia, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-012412

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.